A Review of the Current Clinical Use of Quetiapine and Extended Release Quetiapine in the Management of Anxiety and Related Disorders
Bibliographic record
Abstract
A comprehensive approach to the management of anxiety disorders continues to be a clinical challenge as current therapies have shown only limited efficacy. Quetiapine (available as an immediate-release and an extended-release [XR] formulation) is an atypical antipsychotic agent with primary dopaminergic and serotonergic blocking activity, which has well-established records of clinical efficacy and tolerability in the treatment of schizophrenia and bipolar disorder. Recent controlled trials provide increasing evidence in support of the role of quetiapine XR as both monotherapy and as an augmentation therapy in the treatment of several anxiety disorders, including generalized anxiety disorder, social anxiety disorder, obsessive compulsive disorder, and posttraumatic stress disorder. To date, there is only limited evidence for its use in panic disorder. Quetiapine XR is an important alternative especially for patients who had a partial remission of symptoms or who have not responded to first-line treatments for mood and anxiety disorders. It may also provide an important option in patients whose anxiety disorder is comorbid with an underlying bipolar mood disorder. Quetiapine’s safety and tolerability profile in the management of anxiety disorders is comparable to what is observed when quetiapine is used for other psychiatric conditions, however, it has yet to receive FDA approval for use in generalized anxiety disorder due to potential long-term metabolic adverse effects. Thus, given its efficacy and tolerability, it is important to consider the potential benefit of its ability to manage mood and anxiety disorder symptomatology, while closely monitoring for the more worrisome adverse events. Keywords: Generalized anxiety disorder, obsessive compulsive disorder, panic disorder, post traumatic stress disorder, quetiapine, social anxiety disorder.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.002 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.004 | 0.004 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.004 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".